Dr Adam Edwards

BBiomedSc (Hons), PhD Postdoctoral Research Fellow

In 2019, Dr Adam Edwards completed his PhD at the Perron Institute with Professors Bruno Meloni and Neville Knuckey where he used preclinical models to investigate the role of a novel peptide in preventing a form of brain injury that affects newborn infants. As a postdoctoral researcher, Adam has maintained an active interest in all aspects of infant brain injury, where he continues to investigate further applications of the peptide from his PhD as well as developing new MRI techniques to diagnose acute and chronic infant brain injury.

Publications

Milani D., Clark V.W., Feindel K.W., Blacker D.J., Bynevelt M., Edwards A.B., Anderton R.S., Knuckey N.W., Meloni B.P.
Comparative Assessment of the Proteolytic Stability and Impact of Poly-Arginine Peptides R18 and R18D on Infarct Growth and Penumbral Tissue Preservation Following Middle Cerebral Artery Occlusion in the Sprague Dawley Rat (2021)
Neurochemical Research. 46(5):1166-1176. DOI: 10.1007/s11064-021-03251-y
Edwards A.B., Mastaglia F.L., Knuckey N.W., Meloni B.P.
Neuroprotective Cationic Arginine-Rich Peptides (CARPs): An Assessment of Their Clinical Safety (2020)
Drug Safety. 43(10):957-969. DOI: 10.1007/s40264-020-00962-z
Edwards A.B., Cross J.L., Anderton R.S., Knuckey N.W., Meloni B.P.
Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat (2018)
Molecular Brain. 11(1) DOI: 10.1186/s13041-018-0352-0
Edwards A.B., Anderton R.S., Knuckey N.W., Meloni B.P.
Perinatal hypoxic-ischemic encephalopathy and neuroprotective peptide therapies: A case for cationic arginine-rich peptides (CARPs) (2018)
Brain Sciences. 8(8) DOI: 10.3390/brainsci8080147
Edwards A.B., Anderton R.S., Knuckey N.W., Meloni B.P.
Assessment of therapeutic window for poly-arginine-18D (R18D) in a P7 rat model of perinatal hypoxic-ischaemic encephalopathy (2018)
Journal of Neuroscience Research. 96(11):1816-1826. DOI: 10.1002/jnr.24315
Meloni B.P., Milani D., Cross J.L., Clark V.W., Edwards A.B., Anderton R.S., Blacker D.J., Knuckey N.W.
Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginine–Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats (2017)
NeuroMolecular Medicine. 19(2-Mar):271-285. DOI: 10.1007/s12017-017-8441-2
Chiu L.S., Anderton R.S., Cross J.L., Clark V.W., Edwards A.B., Knuckey N.W., Meloni B.P.
Assessment of R18, COG1410, and APP96-110 in excitotoxicity and traumatic brain injury (2017)
Translational Neuroscience. 8(1):147-157. DOI: 10.1515/tnsci-2017-0021
Edwards A.B., Anderton R.S., Knuckey N.W., Meloni B.P.
Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model (2017)
Molecular and Cellular Biochemistry. 426(1-2):75-85. DOI: 10.1007/s11010-016-2882-z
MacDougall G., Anderton R.S., Edwards A.B., Knuckey N.W., Meloni B.P.
The Neuroprotective Peptide Poly-Arginine-12 (R12) Reduces Cell Surface Levels of NMDA NR2B Receptor Subunit in Cortical Neurons; Investigation into the Involvement of Endocytic Mechanisms (2017)
Journal of Molecular Neuroscience. 61(2):235-246. DOI: 10.1007/s12031-016-0861-1
Edwards A.B., Feindel K.W., Cross J.L., Anderton R.S., Clark V.W., Knuckey N.W., Meloni B.P.
Modification to the Rice-Vannucci perinatal hypoxic-ischaemic encephalopathy model in the P7 rat improves the reliability of cerebral infarct development after 48 hours (2017)
Journal of Neuroscience Methods. 288:62-71. DOI: 10.1016/j.jneumeth.2017.06.016
Meloni B.P., Milani D., Cross J.L., Clark V.W., Edwards A.B., Anderton R.S., Blacker D.J., Knuckey N.W.
Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginine–Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats (2017)
NeuroMolecular Medicine. 19(2-3):271-285. DOI: 10.1007/s12017-017-8441-2
Meloni B.P., Brookes L.M., Clark V.W., Cross J.L., Edwards A.B., Anderton R.S., Hopkins R.M., Hoffmann K., Knuckey N.W.
Poly-arginine and arginine-rich peptides are neuroprotective in stroke models (2015)
Journal of Cerebral Blood Flow and Metabolism. 35(6):993-1004. DOI: 10.1038/jcbfm.2015.11
Meloni B.P., Milani D., Edwards A.B., Anderton R.S., O'Hare Doig R.L., Fitzgerald M., Palmer T.N., Knuckey N.W.
Neuroprotective peptides fused to arginine-rich cell penetrating peptides: Neuroprotective mechanism likely mediated by peptide endocytic properties (2015)
Pharmacology and Therapeutics. 153:36-54. DOI: 10.1016/j.pharmthera.2015.06.002

Latest news

Keep informed with our latest updates.

View all news

Dr Adam Edwards

Publications

Comparative Assessment of the Proteolytic Stability and Impact of Poly-Arginine Peptides R18 and R18D on Infarct Growth and Penumbral Tissue Preservation Following Middle Cerebral Artery Occlusion in the Sprague Dawley Rat (2021)

Neuroprotective Cationic Arginine-Rich Peptides (CARPs): An Assessment of Their Clinical Safety (2020)

Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat (2018)

Perinatal hypoxic-ischemic encephalopathy and neuroprotective peptide therapies: A case for cationic arginine-rich peptides (CARPs) (2018)

Assessment of therapeutic window for poly-arginine-18D (R18D) in a P7 rat model of perinatal hypoxic-ischaemic encephalopathy (2018)

Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginine–Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats (2017)

Assessment of R18, COG1410, and APP96-110 in excitotoxicity and traumatic brain injury (2017)

Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model (2017)

The Neuroprotective Peptide Poly-Arginine-12 (R12) Reduces Cell Surface Levels of NMDA NR2B Receptor Subunit in Cortical Neurons; Investigation into the Involvement of Endocytic Mechanisms (2017)

Modification to the Rice-Vannucci perinatal hypoxic-ischaemic encephalopathy model in the P7 rat improves the reliability of cerebral infarct development after 48 hours (2017)

Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginine–Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats (2017)

Poly-arginine and arginine-rich peptides are neuroprotective in stroke models (2015)

Neuroprotective peptides fused to arginine-rich cell penetrating peptides: Neuroprotective mechanism likely mediated by peptide endocytic properties (2015)

Latest news

Australian Brain Bee Challenge WA 2022

Potential gene therapy for aggressive bone cancer

Publications

Comparative Assessment of the Proteolytic Stability and Impact of Poly-Arginine Peptides R18 and R18D on Infarct Growth and Penumbral Tissue Preservation Following Middle Cerebral Artery Occlusion in the Sprague Dawley Rat (2021)

Neuroprotective Cationic Arginine-Rich Peptides (CARPs): An Assessment of Their Clinical Safety (2020)

Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat (2018)

Perinatal hypoxic-ischemic encephalopathy and neuroprotective peptide therapies: A case for cationic arginine-rich peptides (CARPs) (2018)

Assessment of therapeutic window for poly-arginine-18D (R18D) in a P7 rat model of perinatal hypoxic-ischaemic encephalopathy (2018)

Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginine–Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats (2017)

Assessment of R18, COG1410, and APP96-110 in excitotoxicity and traumatic brain injury (2017)

Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model (2017)

The Neuroprotective Peptide Poly-Arginine-12 (R12) Reduces Cell Surface Levels of NMDA NR2B Receptor Subunit in Cortical Neurons; Investigation into the Involvement of Endocytic Mechanisms (2017)

Modification to the Rice-Vannucci perinatal hypoxic-ischaemic encephalopathy model in the P7 rat improves the reliability of cerebral infarct development after 48 hours (2017)

Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginine–Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats (2017)

Poly-arginine and arginine-rich peptides are neuroprotective in stroke models (2015)

Neuroprotective peptides fused to arginine-rich cell penetrating peptides: Neuroprotective mechanism likely mediated by peptide endocytic properties (2015)

Latest news

Subscribe